5-Amino-1MQ is technically a small molecule rather than a peptide, but it’s sold and researched alongside peptides so consistently that it belongs in the same conversation. It works by inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme that’s drawn significant research interest in metabolic and fat-cell biology.
What NNMT Actually Does
NNMT methylates nicotinamide, consuming a methyl donor (SAM) and a component of the NAD+ salvage pathway in the process. Elevated NNMT activity in adipose tissue has been associated in preclinical research with reduced cellular NAD+ and SAM availability, both of which play roles in fat cell metabolism and energy expenditure.
Why Inhibiting It Is of Research Interest
The logic behind NNMT inhibition research is that reducing this enzyme’s activity could help preserve NAD+ and SAM pools within fat cells, theoretically supporting metabolic flexibility. Most of the foundational research here comes from rodent studies; human data remains much more limited, which is an important distinction from more heavily human-studied compounds like semaglutide.
The Oral Delivery Distinction
Unlike most compounds on this site, 5-Amino-1MQ is typically taken orally rather than reconstituted for injection, which is part of why it’s popular in the “needle-free” research segment alongside oral BPC-157 formulations.
Sourcing
5-Amino-1MQ is sold for research purposes through the following vendors.